Soleno Therapeutics (SLNO) Long-Term Deferred Tax (2014 - 2023)
Soleno Therapeutics' (SLNO) quarterly Long-Term Deferred Tax came in at $66.0 million in Q4 2023, up 4774.8% on a QoQ basis from $1.4 million in Q3 2014.
Soleno Therapeutics (SLNO) Long-Term Deferred Tax (2014 - 2023) Analysis & Trends
Soleno Therapeutics (SLNO) has 2 years of Long-Term Deferred Tax data on file, last reported at $66.0 million in Q4 2023.
- On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $66.0 million in Q4 2023; TTM through Dec 2023 was $66.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $66.0 million, changed N/A from the prior year.
- Long-Term Deferred Tax for Q4 2023 stood at $66.0 million, up from $1.4 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for SLNO reached as high as $66.0 million in Q4 2023 and fell as low as $66.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Soleno Therapeutics | 874.25 Mn | 618.67 Mn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 65.96 Mn |
| Sep 30, 2014 | 1.35 Mn |